The most frequent adverse event was conjunctival hyperemia , which was reported as treatment related in 16.5 % ( 20/121 ) in the bimatoprost/timolol fixed combination group and 18.4 % ( 21/114 ) in the concurrent group ( P > 0.05 ) .